approved more hepatitis direct-acting antivirals (DAAs) for the
treatment of infection with the hepatitis C virus (HCV) by 2020 which
helped low- and middle-income countries increase the
number of registered treatments, reduce prices of a full treatment under
US$100 – update is as low as US$60 for three months, and strive towards
hepatitis C elimination.
the first time, this year’s report includes information on hepatitis C
diagnostics. With a focus on selected countries with diverse…